Drug intelligence / Profile preview

bifidobacterium longum BB536 + lactobacillus rhamnosus HN001

Development stage
Unknown
Modality
Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Bifidobacterium longum BB536 + Lactobacillus rhamnosus HN001 is a combination of two well-characterized probiotic bacterial strains. Both are frequently used as components in dietary supplements aimed at supporting gut health. Bifidobacterium longum BB536 is known for its ability to ferment carbohydrates, producing organic acids (such as acetate and lactate), vitamins, antioxidants, polyphenols, and conjugated linoleic acids. Lactobacillus rhamnosus HN001 also ferments carbohydrates to produce lactic acid and other metabolites beneficial for the intestinal environment[2]. The primary mechanism of action involves modulation of the gut microbiota by promoting a healthy balance of intestinal bacteria, inhibiting the growth of potentially pathogenic gastrointestinal microorganisms (including certain bacteria and Candida species), enhancing production of short-chain fatty acids (SCFAs), improving intestinal barrier function, reducing inflammation, and supporting immune function[1][2][3][6]. This combination has been studied for use in irritable bowel syndrome (IBS) where it improved symptoms and restored intestinal permeability[1], as well as in animal models for effects on infection resistance and potential neuroprotective roles[3][4].

Other names
bifidobacterium longum BB536 and lactobacillus rhamnosus HN001

Beyond the preview

Go deeper on bifidobacterium longum BB536 + lactobacillus rhamnosus HN001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium longum BB536 + lactobacillus rhamnosus HN001.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call